Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio.
Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes :
Each theme is rated taking into account several comprehensive sub-categories.
Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter. Indeed, our process is supported by a network of local experts that have a deep knowledge of each local market best practices (from both customs and regulatory points of views).
If you are interested in the Proxinvest Corporate Governance Rating ®, please contact directly Proxinvest ( or +33(0)1 45 51 50 43).
Novozymes is a biotechnology company based in Denmark. Co.'s business operations are centered on the development of industrial enzymes, microorganisms, and biopharmaceutical ingredients. Co. provides business-to-business biological solutions used in the production of numerous products such as biofuel, detergents, feed, and crops. Co.'s business operations are organized along two segments: the Enzyme Business which is divided into four areas, providing industrial enzymes for household care, food & beverages, bioenergy, and feed & other technical; and the BioBusiness which is home to Co.'s microorganisms and biopharmaceutical ingredients.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Feasibility Study Results in December to be a Catalyst for this Junior
A director at Novozymes A S sold 765,000 shares at 318.970DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boa...
Résolution 1 : la société propose une imputation du report à nouveau débiteur sur le poste « Primes d’émission, de fusion, d’apport ». S’agissant uniquement d’une écriture comptable, qui ne change pas le montant total du passif, cela ne semblerait pas impacter les actionnaires. Par conséquent, Proxinvest recommande l'approbation. Résolution 2 : sachant que la société n’a pas distribué de dividende depuis 2015, Proxinvest juge la demande incohérente au regard de cette privation de dividende et recommande l'opposition. Résolution 4 : suite à la 2ème résolution de la présente assemblée générale...
In general, Adyen is in compliance with the Dutch regulations relating to the organisation and procedures of the Extraordinary General Meeting. Under ITEM 2 it is proposed to re-appoint Mr. Joep van Beurden as member of the supervisory board. The proposed term of appointment of 4 years is in line with provision 2.2.2 of the Dutch Corporate Governance Code. Mr. van Beurden has been board member since 2017 and is currently chairman of the nomination and remuneration committee and member of the audit committee. He is considered independent. ECGS has no concerns over his re-appointment and accord...
MANQUE DE TRANSPARENCE : Encore une fois, nous alertons les actionnaires concernant le manque de transparence de la société Bastide le Confort Médical vis-à-vis de son rapport financier ; tant au niveau des conventions réglementées, tant concernant la politique de rémunération.Par ailleurs, dans le cadre de l’exercice du mandat Monsieur Guy Bastide, ce dernier est assisté par Messieurs Vincent Bastide, Arnaud Fayolle, Olivier Jourdanney, Benoit Quencez et Pierre-Marie Varachaud en qualité de Directeurs Généraux Adjoints. Proxinvest regrette que les rémunérations de Vincent Bastide, Olivier Jou...